BPO   - benzoyl peroxide gel 
Acella Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

BPO 4% Gel and BPO'8% Gel are topical preparations containing benzoyl peroxide 4% and 8%, respectively, as the active ingredient in a gel vehicle containing purified water, aloe barbadensis leaf juice, benzyl alcohOl, cetyl alcohol, dimethyl isosorbide, simethicone, stearyl alcohol and ceteareth-20.

The exact method of action of benzoyl peroxide in acne vulgaris is not known. Benzoyd peroxide is an antibacterial agent with demonstrated  activity against Propionibacterium acnes. This action, combined with the mild keratolytic effect of benzoyl peroxide is believed to be responsible for its usefulness in acne.Benzoyl peroxide is absorbed by the skin where it is metabolized to benzoic acid and excreted as benzoate in the urine.

BPO 4% Gel and BPO 8% Gel are indicated for use in the topical treatment of mild to moderate acne vulgaris. BPO 4% Gel or BPO 8% Gel may be used as an addition in acne treatment regimens including antibiotics, retinoic acid products and sulfur/salicylic acid containing preparations.

BPO 4% Gel and BPO 8% Gel should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the product.

General- For external use only. Avoid contact with eyes and mucous membranes. AVOID CONTACT WITH HAIR, FABRICS OR CARPETING AS BENZOYL PEROXIDE WILL CAUSE BLEACHING.
Carcinogenesis, Mutagenesis, Impairment of FertilityBased upon all available evidence, benzoyl peroxide is not considered to be a carcinogen. However, data from a study using mice known to be highly susceptible to cancer suggest that benzoyl peroxide acts as a turnor promoter. The clinical significance of the findings is not known.
Pregnancy: CategoryC - Animal reproduction studies have not been conducted with benzoyl peroxide. It is also not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed.
Nursing Mothers -It is not known whether this drug is excretec in human milk. Because many drugs are excreted in human milk, caution shOUld be exercised when benzoyl peroxide is administered to a nursing woman.
Pediatric Use - Safety-and effectiveness in children below the age of 1 2 have not been established.

Contact sensitization reactions are associated with the use of topical benzoyl peroxide products and may be expected to occur in 10 to 25 of 1 000 patients. The most frequent adverse reactions associated with benzoyl peroxide use are excessive erythema and peeling which may be expected to occur in 5 of 100 patients. Excessive erythema and peeling most frequently appear during the initial phase of drug use and may normally be controlled by reducing frequency of use .

BPO 4% Gel is supplied in 42.5 g (1.5 oz) tubes NDC42192-1 05-15. BPO 8% Gel is supplied in 42.5 9 (1.5 oz) tubes NDC 421 92-106-15.
Store at controlled room temperature 15°-30°C (59°·86°F).

Manufactured for: Acelia Pharmaceuticals, LLC 9005 Westside Parkway Alpharetta, GA 30009
1 -800-541 -4802
Rev. 12/09

pictures
Tube
Unit Carton

BPO  
benzoyl peroxide gel
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42192-105
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Benzoyl Peroxide (Benzoyl Peroxide) Benzoyl Peroxide4 mg  in 100 mg
Inactive Ingredients
Ingredient NameStrength
ALOE VERA LEAF 
DIMETHYL ISOSORBIDE 
CETYL ALCOHOL 
STEARYL ALCOHOL 
POLYOXYL 20 CETOSTEARYL ETHER 
BENZYL ALCOHOL 
Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMultilevel Packaging
1NDC:42192-105-151 CARTON ( CARTON) in 1 CASEcontains a CARTON
11 TUBE ( TUBE) in 1 CARTONThis package is contained within the CASE (42192-105-15) and contains a TUBE
142500 mg in 1 TUBEThis package is contained within a CARTON and a CASE (42192-105-15)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other01/01/2009

Labeler - Acella Pharmaceuticals, LLC (825380939)
Registrant - Harmony Labs, Inc. (105803274)
Establishment
NameAddressID/FEIOperations
Harmony Labs, Inc.105803274manufacture, label, pack, relabel, repack

Revised: 07/2011 Acella Pharmaceuticals, LLC